CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma

[1]  R. Baric,et al.  Facile discovery of surrogate cytokine agonists , 2022, Cell.

[2]  W. Liu,et al.  An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy , 2022, Nature Cancer.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  N. Reyes,et al.  Binding mechanisms of therapeutic antibodies to human CD20 , 2020, Science.

[5]  M. Huse,et al.  Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies , 2020, Science Translational Medicine.

[6]  N. Meyer,et al.  The TNF Paradox in Cancer Progression and Immunotherapy , 2019, Front. Immunol..

[7]  P. Rossi,et al.  Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas , 2019, Front. Oncol..

[8]  Michael Hummel,et al.  A modular transcriptome map of mature B cell lymphomas , 2019, Genome Medicine.

[9]  L. Sehn,et al.  A tale of two antibodies: obinutuzumab versus rituximab , 2018, British journal of haematology.

[10]  J. Gribben,et al.  Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin , 2018, Haematologica.

[11]  Luke T. Dang,et al.  Surrogate Wnt agonists that phenocopy canonical Wnt/β-catenin signaling , 2017, Nature.

[12]  C. Klein,et al.  Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples , 2017, Rheumatology.

[13]  C. Klein,et al.  A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies , 2016, Advances in Therapy.

[14]  J. M. Lee,et al.  Novel strategy for a bispecific antibody: induction of dual target internalization and degradation , 2016, Oncogene.

[15]  M. Cragg,et al.  Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? , 2016, Drug discovery today.

[16]  Xiaohan Liu,et al.  Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization , 2016, Oncoimmunology.

[17]  B. Bonavida.  Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. , 2014, Seminars in oncology.

[18]  T. Hanafusa,et al.  TNF-&agr; Receptor 1 Expression Predicts Poor Prognosis of Diffuse Large B-cell Lymphoma, Not Otherwise Specified , 2014, The American journal of surgical pathology.

[19]  T. Hanafusa,et al.  TNF-&agr; Expression in Tumor Cells as a Novel Prognostic Marker for Diffuse Large B-cell Lymphoma, Not Otherwise Specified , 2014, The American journal of surgical pathology.

[20]  P. Boya,et al.  High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A , 2014, Cell Death and Differentiation.

[21]  Andrew Leaver-Fay,et al.  Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.

[22]  H. Pelicano,et al.  Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. , 2012, Blood.

[23]  L. Staudt,et al.  Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.

[24]  C. Klein,et al.  CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. , 2011, Blood.

[25]  C. Klein,et al.  Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. , 2011, Blood.

[26]  T. Illidge,et al.  Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. , 2011, Blood.

[27]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[28]  G. Salles,et al.  Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[29]  G. Kroemer,et al.  Lysosomal membrane permeabilization in cell death , 2008, Oncogene.

[30]  Mu-xiang Zhou,et al.  Transmembrane TNF‐α mediates “forward” and “reverse” signaling, inducing cell death or survival via the NF‐κB pathway in Raji Burkitt lymphoma cells , 2008, Journal of leukocyte biology.

[31]  W. Schneider-Brachert,et al.  Regulation of TNFR1 and CD95 signalling by receptor compartmentalization , 2008, Nature Reviews Molecular Cell Biology.

[32]  S. Rajkumar,et al.  Anti‐CD20 monoclonal antibody therapy in multiple myeloma , 2008, British journal of haematology.

[33]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[34]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[35]  D. Kabelitz,et al.  Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. , 2004, Immunity.

[36]  D. Figgitt,et al.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. , 2003, Drugs.

[37]  G. Gores,et al.  Tumor necrosis factor-α-associated lysosomal permeabilization is cathepsin B dependent , 2002 .

[38]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.